Information Provided By: 
Fly News Breaks for November 8, 2019
SRPT
Nov 8, 2019 | 06:00 EDT
Piper Jaffray analyst Danielle Brill says she's happy that Sarepta Therapeutics' Q3 update came with no surprises. While the analyst was hoping to hear an update on next steps for golodirsen, she points out that management made it clear that they won't comment until there's definitive clarity on the path forward. Brill remains bullish and thinks Sarepta is on track for a "transformational" 2020. She keeps an Overweight rating on the shares with a $185 price target.
News For SRPT From the Last 2 Days
There are no results for your query SRPT
